DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 1-20 were originally filed August 10, 2023.
The amendment received April 8, 2026 amended claims 1 and 2 and cancelled claims 9, 12, 14-16, and 20.
Claims 1-8,10, 11, 13, and 17-19 are currently pending and under consideration.
Election/Restrictions
Due to the myriad of issues with the pending claims, the restriction requirement has been withdrawn.
Priority
The present application is a CIP of PCT/CN22/75581 filed February 9, 2022 which claims foreign priority to China 202210110300.x filed January 29, 2022 and China 202110183968.2 filed February 10, 2021.
Please note: the examiner of record is waiting on a translation of PCT/CN22/75581 (WO 2022/171098) to determine priority and why the present application is a CIP.
Acknowledgment is made of applicant's claim for foreign priority based on an application filed in China on January 29, 2022. It is noted, however, that applicant has not filed a certified copy of the 202210110300.x application as required by 37 CFR 1.55.
Acknowledgment is made of applicant's claim for foreign priority based on an application filed in China on February 10, 2021. It is noted, however, that applicant has not filed a certified copy of the 202110183968.2 application as required by 37 CFR 1.55.
Applicant cannot rely upon the certified copy of the foreign priority application to overcome any rejection of record because a translation of said application has not been made of record in accordance with 37 CFR 1.55. When an English language translation of a non-English language foreign application is required, the translation must be that of the certified copy (of the foreign application as filed) submitted together with a statement that the translation of the certified copy is accurate. See MPEP §§ 215 and 216.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on December 18, 2023 is being considered by the examiner.
Nucleotide and/or Amino Acid Sequence Disclosures
Summary of Requirements for Patent Applications Filed On Or After July 1, 2022, That Have Sequence Disclosures
37 CFR 1.831(a) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.831(b) must contain a “Sequence Listing XML”, as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.831-1.835. This “Sequence Listing XML” part of the disclosure may be submitted:
1. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter “Legal Framework”) in XML format, together with an incorporation by reference statement of the material in the XML file in a separate paragraph of the specification (an incorporation by reference paragraph) as required by 37 CFR 1.835(a)(2) or 1.835(b)(2) identifying:
a. the name of the XML file
b. the date of creation; and
c. the size of the XML file in bytes; or
2. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation by reference statement of the material in the XML format according to 37 CFR 1.52(e)(8) and 37 CFR 1.835(a)(2) or 1.835(b)(2) in a separate paragraph of the specification identifying:
a. the name of the XML file;
b. the date of creation; and
c. the size of the XML file in bytes.
SPECIFIC DEFICIENCIES AND THE REQUIRED RESPONSE TO THIS NOTICE ARE AS FOLLOWS:
Specific deficiency - Sequences appearing in the specification are not identified by sequence identifiers (i.e., “SEQ ID NO:X” or the like) in accordance with 37 CFR 1.831(c).
See pages 10, 17, and 27.
Required response – Applicant must provide:
A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125 inserting the required sequence identifiers, consisting of:
• A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);
• A copy of the amended specification without markings (clean version); and
• A statement that the substitute specification contains no new matter.
Specification
The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. See pages 20 and 22.
The disclosure is objected to because of the following informalities: only figures 2 and 7 are described instead of Figures 2A, 2B, 7A, and 7B.
Appropriate correction is required.
The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification.
Sequence Interpretation
The Office interprets claims comprising SEQ ID NOs: in the following manner: “comprising a sequence of SEQ ID NO: 1” requires only a 2mer of SEQ ID NO: 1, “comprising the sequence of SEQ ID NO: 1” requires the full-length sequence with 100% identity to SEQ ID NO: 1 with any N-/C-terminal additions or any 5’/3’ additions, “consisting of SEQ ID NO: 1” requires the full-length sequence with 100% identity to SEQ ID NO: 1 and the same length as SEQ ID NO: 1, and “selected from the group consisting of SEQ ID NOs: 1, 2, and 3” requires the full-length sequence with 100% identity to SEQ ID NOs: 1, 2, or 3 and the same length as SEQ ID NOs: 1, 2, or 3. Any claim requiring a specific percent identity, necessarily requires at least the recited percent identity.
Claim Objections
Claim 1 is objected to because of the following informalities: the colon between (A) and (B) should be “or”. Appropriate correction is required.
Claim 1 is objected to because of the following informalities: “selected from” should read “selected from the group consisting of” and the conjunction should be “and” to correlate with the closed Markush group. Appropriate correction is required. See lines 5, 6, and 8.
Claim 1 is objected to because of the following informalities: the wherein clause for “R/K” is unnecessary (i.e. one of skill in the art would recognize that R is arginine and K is lysine). Appropriate correction is required.
Claim 1 is objected to because of the following informalities: the wherein clause for “S/T/A” is unnecessary (i.e. one of skill in the art would recognize that S is serine, T is threonine, and A is alanine). Appropriate correction is required.
Claim 2 is objected to because of the following informalities: “wherein”, “comprising”, “consisting of”, etc. is missing from the claim. Appropriate correction is required.
Claim 3 is objected to because of the following informalities: personalization of inanimate objects is not typical of scientific writing (i.e. “it has”, “its”, “their”; see (2), (3), and (4)). Appropriate correction is required.
Claim 3 is objected to because of the following informalities: retro-inverted peptide should not be capitalized. Appropriate correction is required.
Claim 4 is objected to because of the following informalities: personalization of inanimate objects is not typical of scientific writing (i.e. “their”; see (1)). Appropriate correction is required.
Claim 5 is objected to because of the following informalities: “selected from” should read “selected from the group consisting of” and the conjunction should be “and” to correlate with the closed Markush group. Appropriate correction is required. See lines 1, 2, 4, 5, 7, and 12.
Claim 6 is objected to because of the following informalities: “comprises cell penetrating peptides” should read “comprises a cell penetrating peptide is”. Appropriate correction is required.
Claim 6 is objected to because of the following informalities: “selected from group of consist” should read “selected from the group consisting of” and the conjunction should be “and” to correlate with the closed Markush group. Appropriate correction is required. See lines 3, 5, and 7.
Claim 7 is objected to because of the following informalities: “amino acid sequences…are” should read “amino acid sequence…is”. Appropriate correction is required.
Claim 7 is objected to because of the following informalities: a conjunction is missing between SEQ ID NOs: 1-3 and SEQ ID NOs: 6-54. Appropriate correction is required.
Claim 7 is objected to because of the following informalities: “amino acid sequences” should read “amino acid sequence”. Appropriate correction is required.
Claim 8 is objected to because of the following informalities: personalization of inanimate objects is not typical of scientific writing (i.e. “its”). Appropriate correction is required.
Claim 10 is objected to because of the following informalities: “and” should be “and/or” to correlate with one or more. Appropriate correction is required.
Claim 11 is objected to because of the following informalities: “selected from” should read “selected from the group consisting of”. Appropriate correction is required.
Claim 11 is objected to because of the following informalities: a single conjunction of “and” should be utilized in the Markush group. See the last two lines. Appropriate correction is required.
Claim 13 is objected to because of the following informalities: articles are missing for anticoagulant and antiplatelet (i.e. “an”). Appropriate correction is required.
Claim 13 is objected to because of the following informalities: unless a trademark, the Markush members of present claim 13 should not be capitalized. Appropriate correction is required.
Claim 13 is objected to because of the following informalities: a conjunction is missing between the two wherein clauses. Appropriate correction is required.
Claim 17 is objected to because of the following informalities: “one of following” should read “one of the following”. Appropriate correction is required.
Claim 17 is objected to because of the following informalities: personalization of inanimate objects is not typical of scientific writing (i.e. “it”, “its”, “their”). Appropriate correction is required.
Claim 17 is objected to because of the following informalities: retro-inverted peptide should not be capitalized. Appropriate correction is required.
Claim 18 is objected to because of the following informalities: “one of following” should read “one of the following”. Appropriate correction is required.
Claim 18 is objected to because of the following informalities: personalization of inanimate objects is not typical of scientific writing (i.e. “their”). Appropriate correction is required.
Claim 19 is objected to because of the following informalities: “one of following” should read “one of the following”. Appropriate correction is required.
Claim 19 is objected to because of the following informalities: personalization of inanimate objects is not typical of scientific writing (i.e. “their”). Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1, 3-6, 10, 11, 13, and 19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. One of skill in the art would not be able to determine the scope of the presently claimed peptides. For example, it is unclear what the scope of “characterized by having” is (i.e. open, closed, etc.).
Claims 1, 3-6, 10, 11, 13, and 19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. One of skill in the art would not be able to determine the scope of the presently claimed peptides. For example, it is unclear if X is actually any amino acid or no amino acid due to the “can be” language. See also the wherein clause for R/K and S/T/A (e.g. does the “can be used” language negate what is required in (A) and (B)).
Claims 1, 3-6, 10, 11, 13, and 19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 1 recites the broad recitation of a peptide of (A) or (B), and the claim also recites a peptide with at most 2 differences with SEQ ID NO: 1 and/or at least 85% identity to SEQ ID NO: 1 which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. For example, a peptide consisting of AAAKKKKAASAAA differs by all 13 amino acids from SEQ ID NO: 1, but still reads on peptide (A).
Claim 2 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. One of skill in the art would not be able to determine the scope of the presently claimed peptides. For example, it is unclear what the scope of “is as shown in” is (e.g. open, closed, etc.).
Claim 3 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. One of skill in the art would not be able to determine the scope of the presently claimed peptides. For example, it is unclear how “based on” alters the artificial interfering peptide of claim 1 (i.e. broadens scope, etc.).
Claim 3 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 3 recites the limitation "the derivative peptide" in line 1 of (4). There is insufficient antecedent basis for this limitation in the claim. The following is suggested: “the derived peptide”.
Claim 5 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 4 recites the broad recitation CPP, ligand, PTD, antibodies, or polymeric materials, and the claim also recites specific species for the CPP and polymeric materials in Markush groups which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims.
Therefore, it is unclear if only the specific species of CPP or polymeric materials are required or not.
Claim 6 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. One of skill in the art would not be able to determine the scope of the presently claimed peptides. For example, it is unclear what the scope of “shown in” is (e.g. open, closed, etc.).
Claim 7 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. One of skill in the art would not be able to determine the scope of the presently claimed peptides. For example, it is unclear what the scope of “shown in” is (e.g. open, closed, etc.).
Claim 8 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. One of skill in the art would not be able to determine the scope of the presently claimed peptides. For example, it is unclear what the scope of “characterized by” is (e.g. open, closed, etc.).
Claim 13 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 13 may contain trademark(s)/trade name(s). Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name.
Applicants are respectfully requested to carefully review the Markush group of claim 13 for any trademark(s)/trade name(s).
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 1-5, 10, 11, 13, and 17-19 are rejected under 35 U.S.C. 101 because the claimed invention is directed to protein kinase fragments without significantly more. The claims recite peptides of (A), (B), or SEQ ID NO: 1. This judicial exception is not integrated into a practical application because the present claimed are drawn to products. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the broad recitations of CPP, ligands, PTD, antibodies, polymeric materials, impurities, excipients, solvents, protectants, adjuvants, carriers, excipients, anticoagulant agent, or antiplatelet agent are well-understood, conventional, and routine in the art. In addition, it is not clear form the claims what the relationship with the peptide is (e.g. structural change or not).
RESULT 1
A0A1A6HVF1_NEOLE
ID A0A1A6HVF1_NEOLE Unreviewed; 66 AA.
AC A0A1A6HVF1;
DT 05-OCT-2016, integrated into UniProtKB/TrEMBL.
DT 05-OCT-2016, sequence version 1.
DT 08-OCT-2025, entry version 29.
DE RecName: Full=Phorbol-ester/DAG-type domain-containing protein {ECO:0000259|PROSITE:PS50081};
DE Flags: Fragment;
GN ORFNames=A6R68_24293 {ECO:0000313|EMBL:OBS81717.1};
OS Neotoma lepida (Desert woodrat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea;
OC Cricetidae; Neotominae; Neotoma.
OX NCBI_TaxID=56216 {ECO:0000313|EMBL:OBS81717.1, ECO:0000313|Proteomes:UP000092124};
RN [1] {ECO:0000313|EMBL:OBS81717.1, ECO:0000313|Proteomes:UP000092124}
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=417 {ECO:0000313|EMBL:OBS81717.1};
RC TISSUE=Liver {ECO:0000313|EMBL:OBS81717.1};
RA Campbell M., Oakeson K.F., Yandell M., Halpert J.R., Dearing D.;
RT "The Draft Genome Sequence and Annotation of the Desert Woodrat Neotoma
RT lepida.";
RL Submitted (JUN-2016) to the EMBL/GenBank/DDBJ databases.
CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|ARBA:ARBA00004496}.
CC Membrane {ECO:0000256|ARBA:ARBA00004370}.
CC -!- CAUTION: The sequence shown here is derived from an EMBL/GenBank/DDBJ
CC whole genome shotgun (WGS) entry which is preliminary data.
CC {ECO:0000313|EMBL:OBS81717.1}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; LZPO01009949; OBS81717.1; -; Genomic_DNA.
DR AlphaFoldDB; A0A1A6HVF1; -.
DR STRING; 56216.A0A1A6HVF1; -.
DR OrthoDB; 74314at2759; -.
DR Proteomes; UP000092124; Unassembled WGS sequence.
DR GO; GO:0005829; C:cytosol; IEA:TreeGrafter.
DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR GO; GO:0035556; P:intracellular signal transduction; IEA:TreeGrafter.
DR GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IEA:TreeGrafter.
DR FunFam; 3.30.60.20:FF:000021; Serine/threonine-protein kinase; 1.
DR Gene3D; 3.30.60.20; -; 1.
DR InterPro; IPR046349; C1-like_sf.
DR InterPro; IPR002219; PKC_DAG/PE.
DR PANTHER; PTHR22968; PROTEIN KINASE C, MU; 1.
DR PANTHER; PTHR22968:SF9; SERINE_THREONINE-PROTEIN KINASE D1; 1.
DR Pfam; PF00130; C1_1; 1.
DR SUPFAM; SSF57889; Cysteine-rich domain; 1.
DR PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE 4: Predicted;
KW Cytoplasm {ECO:0000256|ARBA:ARBA00022490};
KW Kinase {ECO:0000256|ARBA:ARBA00022777};
KW Membrane {ECO:0000256|ARBA:ARBA00023136};
KW Metal-binding {ECO:0000256|ARBA:ARBA00022723};
KW Reference proteome {ECO:0000313|Proteomes:UP000092124};
KW Repeat {ECO:0000256|ARBA:ARBA00022737};
KW Serine/threonine-protein kinase {ECO:0000256|ARBA:ARBA00022527};
KW Transferase {ECO:0000256|ARBA:ARBA00022679};
KW Zinc {ECO:0000256|ARBA:ARBA00022833};
KW Zinc-finger {ECO:0000256|ARBA:ARBA00022771}.
FT DOMAIN 1..31
FT /note="Phorbol-ester/DAG-type"
FT /evidence="ECO:0000259|PROSITE:PS50081"
FT NON_TER 66
FT /evidence="ECO:0000313|EMBL:OBS81717.1"
SQ SEQUENCE 66 AA; 7270 MW; C1E3A93F516EC54F CRC64;
Query Match 100.0%; Score 60; Length 66;
Best Local Similarity 100.0%;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 SGVRRRRLSNVSL 13
|||||||||||||
Db 32 SGVRRRRLSNVSL 44
Please note: due to the myriad of issues with the claims (i.e. see above objections, 35 USC 112 rejections above, additional issues of convoluted language, etc.), the examiner of record is providing rewritten claims.
An artificial short interfering peptide for the phosphorylation substrate of DAPK1, consisting of XXX(R/K)(R/K)(R/K)(R/K)X2(S/T/A)X1XXX or XXX(R/K)(R/K)(R/K)X2(R/K)(S/T/A)X1XXX
each X is independently selected from the group consisting of any amino acid or no amino acid,
X1 is selected from the group consisting of N, C, Q, S, and T, and
X2 is selected from the group consisting of A, I, L, M, and V.
The artificial short interfering peptide according to claim 1, consisting of any one of SEQ ID NOs: 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38.
The artificial short interfering peptide according to claim 1 wherein the artificial short interfering peptide is (a) stapled; (b) cyclic via head-to-tail cyclization, side chain cyclization, thioester bond cyclization, lactone bond cyclization, oxidized Se-Cys to form a ring, or disulfide bond cyclization; (c) a reverse peptide in C-terminus to N-terminus order; (d) a retro-inverso peptide; or (e) comprises at least one D-amino acid or b-homo-amino acid.
A polypeptide comprising (a) two or more artificial short interfering peptides according to claim 1 polymerized in parallel with the C-termini free and the N-termini aggregated together and connected to a delivery carrier or (b) a fusion polypeptide comprising the artificial short interfering peptide according to claim 1 fused at the N- and/or C-terminus to one or more delivery carrier(s).
The polypeptide according to claim 4 wherein the delivery carrier is selected from the group consisting of a ligand, a protein transduction domain (PTD), an antibody, a cationic cell-penetrating peptide (CPP), an amphipathic CPP, a hydrophobic CPP, a synthetic CPP, polyethylene glycol (PEG), polylactic acid, poly(lactide-co-glycolide), polyglycolic acid (PGA), polycaprolactone (PCA), polyethylene oxide (PEO), polydioxanone (PDS), polypropylene fumarate, trimethylene carbonate, polyamide epoxy, ester amide, b-hydroxyalkyl methacrylate, a-hydroxy acid, polyhydroxyalkanoate, polyhydroxybutyrate, polyimide carbonate, polyanhydride, polyacid anhydride, hyaluronic acid, chitosan, cellulose, gelatin, and collagen.
The polypeptide according to claim 4, wherein the cationic CPP is selected from the group consisting of SEQ ID NOs: 55-72, the amphipathic CPP is selected from the group consisting of SEQ ID NOs: 73-81, the hydrophobic CPP is selected from the group consisting of SEQ ID NOs: 82-85, or the artificial CPP consists of SEQ ID NO: 86.
The polypeptide according to claim 6, wherein the artificial short interfering peptide is selected from the group consisting of SEQ ID NOs: 1-3 and 6-54 and the CPP is selected from the group consisting of SEQ ID NOs: 55-86.
The polypeptide according to claim 7, selected from the group consisting of SEQ ID NOs: 87-96.
A medicine comprising (a) the artificial short interfering peptide of claim 1 or (b) a modified artificial short interfering peptide of claim 1 wherein the modification is an N-terminal modification, a C-terminal modification, a label, cyclization, lipidation, N-methylation, acetylation, palmitoylation, glycosylation, biotinylation, PEGylation, and/or a fluorescent label and further comprising a pharmaceutically acceptable impurity, excipient, solvent, protectant, adjuvant, and/or carrier.
The medicine according to claim 10, formulated as an inhalation aerosol, an oral formulation, an intravenous formulation, an intraarterial formulation, an intracranial formulation, an intraperitoneal formulation, an intranasal formulation, an intramuscular formulation, a subcutaneous formulation, an intraarticular formulation, an intracavity formulation, a sternal formulation, or an intraspinal formulation.
A pharmaceutical composition comprising the medicine according to claim 10 and an anticoagulant agent selected from the group consisting of acenocoumarol, warfarin,…brinase, and combinations thereof or an antiplatelet agent selected from the group consisting of clopidogrel, ticagrelor,…ditazol, and combinations thereof.
The artificial short interfering peptide according to claim 2 wherein the artificial short interfering peptide is (a) stapled; (b) cyclic via head-to-tail cyclization, side chain cyclization, thioester bond cyclization, lactone bond cyclization, oxidized Se-Cys to form a ring, or disulfide bond cyclization; (c) a reverse peptide in C-terminus to N-terminus order; (d) a retro-inverso peptide; or (e) comprises at least one D-amino acid or b-homo-amino acid.
A polypeptide comprising (a) two or more artificial short interfering peptides according to claim 2 polymerized in parallel with the C-termini free and the N-termini aggregated together and connected to a delivery carrier or (b) a fusion polypeptide comprising the artificial short interfering peptide according to claim 2 fused at the N- and/or C-terminus to one or more delivery carrier(s).
A polypeptide comprising (a) two or more artificial short interfering peptides according to claim 3 polymerized in parallel with the C-termini free and the N-termini aggregated together and connected to a delivery carrier or (b) a fusion polypeptide comprising the artificial short interfering peptide according to claim 3 fused at the N- and/or C-terminus to one or more delivery carrier(s).
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
WO 2004/039943
U.S. Patent Application Publication 2002/0055160
Future Communications
Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMBER D STEELE whose telephone number is (571)272-5538. The examiner can normally be reached M-F 8-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/AMBER D STEELE/Primary Examiner, Art Unit 1658
Prosecution Insights